These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

975 related items for PubMed ID: 15550531

  • 1. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X, Club Rheumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [Abstract] [Full Text] [Related]

  • 2. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X.
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [Abstract] [Full Text] [Related]

  • 3. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [Abstract] [Full Text] [Related]

  • 4. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS.
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [Abstract] [Full Text] [Related]

  • 5. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
    El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP.
    J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
    [Abstract] [Full Text] [Related]

  • 6. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG, Jones RB, Burns SM, Jayne DR.
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [Abstract] [Full Text] [Related]

  • 8. The risk of lymphoma development in autoimmune diseases: a meta-analysis.
    Zintzaras E, Voulgarelis M, Moutsopoulos HM.
    Arch Intern Med; 2005 Nov 14; 165(20):2337-44. PubMed ID: 16287762
    [Abstract] [Full Text] [Related]

  • 9. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J, BIOGEAS Study Group.
    Clin Exp Rheumatol; 2010 Nov 14; 28(4):468-76. PubMed ID: 20525449
    [Abstract] [Full Text] [Related]

  • 10. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
    De Jesus A, Talal N.
    Crit Care Med; 1990 Feb 14; 18(2 Suppl):S132-7. PubMed ID: 2298028
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X, Club Rhumatismes et Inflammations and the French Society of Rheumatology.
    Ann Rheum Dis; 2013 Jun 14; 72(6):1026-31. PubMed ID: 23264337
    [Abstract] [Full Text] [Related]

  • 12. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
    Fleischmann RM.
    Semin Arthritis Rheum; 2009 Feb 14; 38(4):265-80. PubMed ID: 18336874
    [Abstract] [Full Text] [Related]

  • 13. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B, French Pediatric-Onset SLE Study Group.
    J Pediatr; 2006 May 14; 148(5):623-627. PubMed ID: 16737873
    [Abstract] [Full Text] [Related]

  • 14. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N, Gossec L, Dieudé P, Meyer O, Dougados M, Kahan A, Allanore Y.
    J Rheumatol; 2008 Jan 14; 35(1):31-4. PubMed ID: 18176989
    [Abstract] [Full Text] [Related]

  • 15. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option.
    Yoon KH.
    Ann N Y Acad Sci; 2009 Sep 14; 1173():752-6. PubMed ID: 19758225
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
    Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE, Club Rhumatismes et Inflammation.
    Arthritis Rheum; 2010 Aug 14; 62(8):2458-66. PubMed ID: 20506527
    [Abstract] [Full Text] [Related]

  • 17. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
    Ebo D, DeClerck LS, Bridts CH, Stevens WJ.
    In Vivo; 1994 Aug 14; 8(4):577-80. PubMed ID: 7534494
    [Abstract] [Full Text] [Related]

  • 18. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR.
    Int Immunopharmacol; 2009 Jan 14; 9(1):10-25. PubMed ID: 19000786
    [Abstract] [Full Text] [Related]

  • 19. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
    Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Rueda JC, Anaya JM.
    Clin Rev Allergy Immunol; 2008 Feb 14; 34(1):124-8. PubMed ID: 18270866
    [Abstract] [Full Text] [Related]

  • 20. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.
    Rheumatology (Oxford); 2007 Jun 14; 46(6):980-2. PubMed ID: 17384180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.